# A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Study · id `cardio:ct-nct05649137` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05649137](<https://clinicaltrials.gov/study/NCT05649137>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05649137

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 512 participants.

## Technical summary

Registry record NCT05649137. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-04 (actual); primary completion 2024-10-28 (actual). Results posted on 2026-04-27.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 512 participants (enrolled count; ClinicalTrials.gov record NCT05649137, source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)
- Started: 2023-01-04 (actual) (ClinicalTrials.gov record NCT05649137, source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)
- Primary completion: 2024-10-28 (actual) (ClinicalTrials.gov record NCT05649137, source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)
- Completion: 2024-12-13 (actual) (ClinicalTrials.gov record NCT05649137, source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)
- Results first posted: 2026-04-27 (ClinicalTrials.gov record NCT05649137, source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)
- Countries: United States; Bulgaria; Canada; Hungary; Poland; Portugal; Slovakia; South Africa (ClinicalTrials.gov record NCT05649137, source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05649137-2026-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
- Condition: Obesity
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Semaglutide
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial (`cardio:pubmed-40961953`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 558f78f717417c29bf42719c47e8d75fbaa681111ea9b25f5c51fe3d3fe39dd2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
